Repeated colonization by multi-drug-resistant Acinetobacter calcoaceticus-A. baumannii complex and changes in antimicrobial susceptibilities in surgical intensive care units

Surg Infect (Larchmt). 2013 Feb;14(1):43-8. doi: 10.1089/sur.2012.044. Epub 2013 Feb 20.

Abstract

Background: A nosocomial outbreak of multi-drug-resistant Acinetobacter calcoaceticus-A. baumannii (MDR-ACB) complex infection occurred in a newly constructed building at a 2,500-bed tertiary medical center in Taiwan.

Methods: An investigation was carried out by molecular approaches to trace the bacteria. Antimicrobial susceptibilities, risk factors, and the occurrence of nosocomial MDR-ACB infections were investigated. From January to December 2009, 53 patients were infected with MDR-ACB, and 23 environmental surveys were performed in two surgical intensive care units (ICUs) within the new building. Forty-two clinical isolates were obtained from patients and 22 samples from nine environmental surveys.

Results: Forty clinical isolates (95.2%) and 18 environmental samples (81.8%) were positive for MDR-ACB of type A, the predominant outbreak strain. This strain was identical to that isolated in an outbreak in the old hospital in 2006, as proved by repetitive extragenic palindromic-based polymerase chain reaction and pulsed-field gel electrophoresis. Although the outbreak isolates contained blaOXA-23-like and blaOXA-51-like genes, analysis of the antimicrobial susceptibilities demonstrated increases in resistance to cefepime and imipenem-cilastatin in MDR-ACB isolated in the later outbreak.

Conclusions: Not only patients or healthcare workers, but also medical equipment, might have carried the predominant outbreak strain from the old district to the new building. Therefore, even in a new environment, infection control programs must be enforced continually, and healthcare providers must be educated repeatedly to prevent recurrent outbreaks of MDR-ACB infection in the hospital setting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter / drug effects*
  • Acinetobacter / genetics
  • Acinetobacter / growth & development*
  • Acinetobacter / isolation & purification
  • Acinetobacter Infections / microbiology*
  • Anti-Bacterial Agents / pharmacology
  • Cefepime
  • Cephalosporins / pharmacology
  • Chi-Square Distribution
  • China
  • Cilastatin / pharmacology
  • Cilastatin, Imipenem Drug Combination
  • Critical Care
  • Cross Infection / microbiology*
  • Disease Outbreaks
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial
  • Electrophoresis, Gel, Pulsed-Field
  • Humans
  • Imipenem / pharmacology
  • Microbial Sensitivity Tests
  • Public Health Surveillance
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Drug Combinations
  • Cilastatin
  • Imipenem
  • Cefepime
  • Cilastatin, Imipenem Drug Combination